Payment overview · 2025
General Payments
$47,902.13
153 reported records · 20 companies
Healthcare provider profile · identity verified
Iftekhar Baig, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BRADENTON, FL · NPI 1750661419
Verified facts
What the public records show
CMS Open Payments records show Iftekhar Baig, D.O. received $47,902.13 in general payments during 2025 across 153 reported records.
Shockwave Medical, Inc accounted for 57.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $27,551.60 | 57.5% | 21 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$10,063.37 | 21.0% | 40 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $5,145.19 | 10.7% | 9 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $2,315.73 | 4.8% | 15 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $978.09 | 2.0% | 20 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $387.95 | 0.8% | 17 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $332.20 | 0.7% | 5 | 2025 |
| Contego Medical, Inc | Unresolved — no canonical attribution shown | $279.26 | 0.6% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $265.45 | 0.6% | 2 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $162.84 | 0.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $109.16 | 0.2% | 6 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $54.99 | 0.1% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $52.23 | 0.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.54 | 0.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.38 | 0.1% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $39.58 | 0.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.56 | 0.1% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $19.53 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.98 | 0.0% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $15.50 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $18,562.50 | 6 |
| Travel and Lodging | $11,062.78 | 12 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,743.75 | 4 |
| Food and Beverage | $6,033.10 | 129 |
| Honoraria | $4,500.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $27,413.17 | 18 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $5,240.87 | 17 | 2025 |
Source payment records
|
|||||
| US EQ Undivided Normalized: us eq undivided |
Device | Philips North America LLC | $4,582.16 | 3 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $1,630.63 | 6 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $943.09 | 16 | 2025 |
Source payment records
|
|||||
| EVERCROSS Normalized: evercross |
Device | Medtronic, Inc. | $562.50 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $483.39 | 2 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $388.34 | 6 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $374.19 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $361.56 | 16 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $360.82 | 5 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $332.20 | 5 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $310.91 | 6 | 2025 |
Source payment records
|
|||||
| ELLIPSYS VASCULAR ACCESS SYSTEM Normalized: ellipsys vascular access system |
Device | Medtronic, Inc. | $300.64 | 2 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $265.45 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $162.84 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $162.84 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $102.92 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $87.76 | 5 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $52.23 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.54 | 3 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $36.20 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $35.00 | 4 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| VENACORE THROMBECTOMY CATHETER Normalized: venacore thrombectomy catheter |
Device | Stryker Corporation | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $9.38 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $6.08 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $3.07 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $1.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 278 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
278 | 71 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Tartrate | Metoprolol Tartrate | 332 | 108 |
| Eliquis | Apixaban | 278 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 256 | 84 |
| Lisinopril | Lisinopril | 225 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 210 | 72 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 180 | 56 |
| Losartan Potassium | Losartan Potassium | 114 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 42 |
| Spironolactone | Spironolactone | 103 | 31 |
| Xarelto | Rivaroxaban | 97 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 31 |
| Furosemide | Furosemide | 90 | 35 |
| Carvedilol | Carvedilol | 56 | 21 |
| Ezetimibe | Ezetimibe | 56 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Brilinta | Ticagrelor | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47,902.13 · 153 records | Shockwave Medical, Inc | ABRE, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, AZURE XT DR MRI SURESCAN, Barostim Neo System, ECC Solutions, ELIQUIS, ELLIPSYS VASCULAR ACCESS SYSTEM, ELUVIA, ENDOCROSS Device, ENROUTE Transcarotid Neuroprotection System, ENTRESTO, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, EVERCROSS, EkoSonic, Extended Holter, FARXIGA, HAWKONE, IGT Devices Undivided, IN.PACT ADMIRAL, IN.PACT AV, Indigo System, LEQVIO, Labosys, MYCARELINK, OPTOWIRE, Ozempic, Penumbra System, REPATHA, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TURBOHAWK, Torus Stent Graft System, US EQ Undivided, VENACORE THROMBECTOMY CATHETER, VERQUVO, VYNDAQEL, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error